FDA Inspection 859089 — Abrams Royal Pharmacy

Abrams Royal Pharmacy — FEI 1000138425

The FDA completed an inspection of Abrams Royal Pharmacy on December 20, 2013 in Dallas, TX. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 12 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
December 20, 2013
Fiscal Year
2014
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Dallas, TX (United States)

Citations

IDCFRDescription
103321 CFR 211.22(a)Authority lacking to review records, investigate errors
116921 CFR 211.42(a)Buildings of Suitable Size, Construction, Location
143421 CFR 211.42(c)(10)(iv)Environmental Monitoring System
143521 CFR 211.42(c)(10)(v)Cleaning System
145121 CFR 211.113(b)Procedures for sterile drug products
179021 CFR 211.80(b)Handling and Storage to Prevent Contamination
191421 CFR 211.166(a)Lack of written stability program
193221 CFR 211.167(a)Sterility/pyrogen-free testing
200921 CFR 211.188Prepared for each batch, include complete information
360321 CFR 211.160(b)Scientifically sound laboratory controls
361321 CFR 211.160(b)(4)Establishment of calibration procedures
438921 CFR 211.198(a)Procedures to be written and followed